Minimal residual disease in periphral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F11%3A%230001333" target="_blank" >RIV/65269705:_____/11:#0001333 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3324/haematol.2011.042937" target="_blank" >http://dx.doi.org/10.3324/haematol.2011.042937</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2011.042937" target="_blank" >10.3324/haematol.2011.042937</a>

Result language
angličtina
Original language name
Minimal residual disease in periphral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis
Original language description
Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NS10472" target="_blank" >NS10472: Dynamics of extramedullary involvement during pediatric precursor-B acute lymphoblastic leukemia treatment</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)